In combination with pemetrexed and platinum chemotherapy as first-line treatment of patients with advanced or metastatic non-squamous NSCLC, with no EGFR or ALK genomic tumor aberrations. This evidence concerns the gene EGFR and non-small cell lung carcinoma.